Your browser doesn't support javascript.
loading
Galanin System in the Human Bile Duct and Perihilar Cholangiocarcinoma.
Huber, Sara; Fitzner, Theresia; Feichtinger, René G; Hochmann, Sarah; Kraus, Theo; Sotlar, Karl; Kofler, Barbara; Varga, Martin.
Affiliation
  • Huber S; Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
  • Fitzner T; Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
  • Feichtinger RG; Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
  • Hochmann S; Cell Therapy Institute, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, 5020 Salzburg, Austria.
  • Kraus T; Department of Pathology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
  • Sotlar K; Department of Pathology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
  • Kofler B; Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
  • Varga M; Department of Surgery, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
Cells ; 12(13)2023 06 21.
Article in En | MEDLINE | ID: mdl-37443714
ABSTRACT

BACKGROUND:

Perihilar cholangiocarcinoma (pCCA) is characterised by poor outcomes. Early diagnosis is essential for patient survival. The peptide galanin (GAL) and its receptors GAL1-3 are expressed in various tumours. Detailed characterisation of the GAL system in pCCA is lacking. Our study sought to characterise GAL and GAL1-3 receptor (GAL1-3-R) expression in the healthy human bile duct, in cholestasis and pCCA.

METHODS:

Immunohistochemical staining was performed in healthy controls (n = 5) and in the peritumoural tissues (with and without cholestasis) (n = 20) and tumour tissues of pCCA patients (n = 33) using validated antibodies. The score values of GAL and GAL1-3-R expression were calculated and statistically evaluated.

RESULTS:

GAL and GAL1-R were expressed in various bile duct cell types. GAL2-R was only slightly but still expressed in almost all the examined tissues, and GAL3-R specifically in cholangiocytes and capillaries. In a small pCCA patient cohort (n = 18), high GAL expression correlated with good survival, whereas high GAL3-R correlated with poor survival.

CONCLUSIONS:

Our in-depth characterisation of the GAL system in the healthy human biliary duct and pCCA in a small patient cohort revealed that GAL and GAL3-R expression in tumour cells of pCCA patients could potentially represent suitable biomarkers for survival.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bile Duct Neoplasms / Cholestasis / Klatskin Tumor / Peptide Hormones Type of study: Screening_studies Limits: Humans Language: En Journal: Cells Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bile Duct Neoplasms / Cholestasis / Klatskin Tumor / Peptide Hormones Type of study: Screening_studies Limits: Humans Language: En Journal: Cells Year: 2023 Document type: Article Affiliation country: